Adjuvant Nivolumab Beneficial in Esophageal, GE Junction Cancer
A study found that patients with gastroesophageal junction cancer who were treated with surgery and chemoradiotherapy had significantly longer disease-free survival if... Read More
FDA Approves Nivolumab Plus Chemo for Frontline Advanced Gastric Cancer
The FDA approved the first immunotherapy for the first-line treatment of advanced gastric cancer, Bristol Myers Squibb’s Opdivo in combination with chemotherapy.
Heavy Alcohol Use Is Associated With Gastric Cancer
A study in the American Journal of Gastroenterology found an association between heavy alcohol use and an increased risk of gastric cancer.
Patients Aged 70 or Older With Esophageal or EGJ Cancers Should Be Evaluated for Optimal Curative Therapy
A recent study found that patients over 70 with esophageal cancers benefited from “triple modality” surgery that included surgery, with five-year survival... Read More
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Platinum- and Fluoropyrimidine-Based Chemotherapy for Treatment of Certain Patients With Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction (GEJ) Carcinoma
Merck received FDA approval for Keytruda plus chemotherapy for some patients with advanced esophageal or gastroesophageal junction cancer.
Ambrx Granted Orphan Drug Designation for ARX788 for the Treatment of Gastric Cancer
Ambrx was granted orphan drug designation by the FDA for its drug ARX788, which is in clinical trials to treat HER2-positive gastric... Read More
Zolbetuximab Plus EOX vs EOX Alone for First-Line Treatment of Advanced CLDN18.2-Positive Gastric and Gastro-Oesophageal Adenocarcinoma
In a phase 2 trial in advanced gastric cancer with high expression of CLDN18.2, adding Ganymed Pharmaceuticals’experimental drug zolbetuximab to chemotherapy improved... Read More
Safety and feasibility of minimally invasive surgical interventions for esophageal and gastric cancer in the acute setting
Dutch researchers found in a recent study that minimally invasive surgery in gastric cancer is safe, feasible and offers comparable short-term outcomes... Read More
New Published Research from the Gastric Cancer Registry Team
Our Gastric Cancer Registry project at Stanford is leading to important research and new discoveries. A recently published study used joint single... Read More
Quality of Life Maintained With Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
A study presented at ASCO GI found that the immunotherapy drug Opdivo given to gastric cancer patients after surgery lowers relapse risk... Read More
